Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ET
Fulcrum Therapeutics (Nasdaq: FULC) announced that it will release its third quarter 2020 financial results on November 10, 2020, before U.S. markets open. A conference call and webcast will be held at 8:00 a.m. ET to discuss the results and corporate updates. The company specializes in treating genetically defined rare diseases, with products like losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease. For additional information, visit their Investor Relations webpage.
- None.
- None.
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2020 financial results will be released on Tuesday, November 10, 2020 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 2408316
Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 2408316
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.
Please visit www.fulcrumtx.com.
Contact:
Christi Waarich
Director, Investor Relations and
Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com
FAQ
When will Fulcrum Therapeutics announce its third quarter 2020 financial results?
What time is the conference call for Fulcrum Therapeutics' Q3 results?
What are the key products being developed by Fulcrum Therapeutics?
How can I access the live webcast for Fulcrum Therapeutics' financial results?
